{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:34:54Z","timestamp":1707525294028},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,29]]},"DOI":"10.7759\/cureus.46202","type":"journal-article","created":{"date-parts":[[2023,9,29]],"date-time":"2023-09-29T14:02:16Z","timestamp":1695996136000},"source":"Crossref","is-referenced-by-count":0,"title":["Management of Bevacizumab-Induced Proteinuria Using an Angiotensin Receptor Blocker (ARB) in a Neurofibromatosis Type 2 (NF-2) Patient With Vestibular Schwannoma"],"prefix":"10.7759","author":[{"given":"Egiroh E","family":"Omene","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Easaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60259-2","article-title":"Neurofibromatosis type 2","volume":"373","author":"Asthagiri AR","year":"2009","unstructured":"Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR. Neurofibromatosis type 2. Lancet. 2009, 373:1974-86. 10.1016\/S0140-6736(09)60259-2","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1593\/neo.111600","article-title":"Merlin\/NF2 regulates angiogenesis in schwannomas through a Rac1\/semaphorin 3F-dependent mechanism","volume":"14","author":"Wong HK","year":"2012","unstructured":"Wong HK, Shimizu A, Kirkpatrick ND, et al.. Merlin\/NF2 regulates angiogenesis in schwannomas through a Rac1\/semaphorin 3F-dependent mechanism. Neoplasia. 2012, 14:84-94. 10.1593\/neo.111600","journal-title":"Neoplasia"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/lary.27586","article-title":"Progression of hearing loss in neurofibromatosis type 2 according to genetic severity","volume":"129","author":"Emmanouil B","year":"2019","unstructured":"Emmanouil B, Houston R, May A, et al.. Progression of hearing loss in neurofibromatosis type 2 according to genetic severity. Laryngoscope. 2019, 129:974-80. 10.1002\/lary.27586","journal-title":"Laryngoscope"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-4-16","article-title":"Neurofibromatosis type 2 (NF2): a clinical and molecular review","volume":"4","author":"Evans DG","year":"2009","unstructured":"Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. Orphanet J Rare Dis. 2009, 4:16. 10.1186\/1750-1172-4-16","journal-title":"Orphanet J Rare Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2013.12.010","article-title":"Incidental parenchymal magnetic resonance imaging findings in the brains of patients with neurofibromatosis type 2","volume":"4","author":"Vargas WS","year":"2014","unstructured":"Vargas WS, Heier LA, Rodriguez F, Bergner A, Yohay K. Incidental parenchymal magnetic resonance imaging findings in the brains of patients with neurofibromatosis type 2. Neuroimage Clin. 2014, 4:258-65. 10.1016\/j.nicl.2013.12.010","journal-title":"Neuroimage Clin"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.03.073","article-title":"Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors","volume":"73","author":"Wentworth S","year":"2009","unstructured":"Wentworth S, Pinn M, Bourland JD, et al.. Clinical experience with radiation therapy in the management of neurofibromatosis-associated central nervous system tumors. Int J Radiat Oncol Biol Phys. 2009, 73:208-13. 10.1016\/j.ijrobp.2008.03.073","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1159\/000485526","article-title":"Hearing rehabilitation in neurofibromatosis type 2","volume":"81","author":"North HJ","year":"2018","unstructured":"North HJ, Lloyd SK. Hearing rehabilitation in neurofibromatosis type 2. Adv Otorhinolaryngol. 2018, 81:93-104. 10.1159\/000485526","journal-title":"Adv Otorhinolaryngol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis MA","year":"2012","unstructured":"Karajannis MA, Legault G, Hagiwara M, et al.. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol. 2012, 14:1163-70. 10.1093\/neuonc\/nos146","journal-title":"Neuro Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin SR","year":"2009","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, et al.. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009, 361:358-67. 10.1056\/NEJMoa0902579","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012424","article-title":"Patient report of hearing in neurofibromatosis type 2: recommendations for clinical trials","volume":"97","author":"Thompson HL","year":"2021","unstructured":"Thompson HL, Blanton A, Franklin B, Merker VL, Franck KH, Welling DB. Patient report of hearing in neurofibromatosis type 2: recommendations for clinical trials. Neurology. 2021, 97:S64-72.","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.83","article-title":"Incidence of hypertension and proteinuria in patients","volume":"39","author":"Man Y","year":"2021","unstructured":"Man Y, Han Y, Mukherjee S, Zalewski O. Incidence of hypertension and proteinuria in patients. J Clin Oncol. 2021, 39:83. 10.1200\/JCO.2021.39.3_suppl.83","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu S","year":"2010","unstructured":"Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010, 21:1381-9. 10.1681\/ASN.2010020167","journal-title":"J Am Soc Nephrol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2174\/1381612811319170009","article-title":"Angiotensin II blockade and renal protection","volume":"19","author":"Kobori H","year":"2013","unstructured":"Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. Curr Pharm Des. 2013, 19:3033-42. 10.2174\/1381612811319170009","journal-title":"Curr Pharm Des"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/1470320312474054","article-title":"Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials","volume":"15","author":"Geng DF","year":"2014","unstructured":"Geng DF, Sun WF, Yang L, En G, Wang JF. Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials. J Renin Angiotensin Aldosterone Syst. 2014, 15:44-51. 10.1177\/1470320312474054","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd4816","article-title":"Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models","volume":"13","author":"Wu L","year":"2021","unstructured":"Wu L, Vasilijic S, Sun Y, et al.. Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Sci Transl Med. 2021, 13:4816. 10.1126\/scitranslmed.abd4816","journal-title":"Sci Transl Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/161856-management-of-bevacizumab-induced-proteinuria-using-an-angiotensin-receptor-blocker-arb-in-a-neurofibromatosis-type-2-nf-2-patient-with-vestibular-schwannoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:09:54Z","timestamp":1707509394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/161856-management-of-bevacizumab-induced-proteinuria-using-an-angiotensin-receptor-blocker-arb-in-a-neurofibromatosis-type-2-nf-2-patient-with-vestibular-schwannoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.46202","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,29]]}}}